Clinical study on Yixiao Decoction in the treatment of type 2 diabetes complicated with left ventricular diastolic dysfunctio
- Conditions
- Type 2 Diabetes
- Registration Number
- ITMCTR2100004708
- Lead Sponsor
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1.Aged >40 and <75 years;
2.Meet the diagnosis of type 2 diabetes;
3.Meet the diagnosis of left ventricular diastolic dysfunction;
4.Meet the TCM diagnosis of Qi and yin deficiency and blood stasis syndrome;
5.Patients who are able to correctly describe their wishes, voluntarily fill in the informed consent form and agree to participate in clinical trials.
1.Left ventricular ejection fraction < 50%;
2.Patients with type 1 diabetes and other types of diabetes;
3.Patients with rheumatic valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy and other heart diseases have been definitely diagnosed;
4.Patients with acute or severe complications of diabetes, such as ketoacidosis, hyperosmolar coma, infection, etc;
5.Patients with chronic wasting diseases such as immune system diseases and malignant tumors;
6.Patients with severe renal failure, liver coma and other visceral dysfunction, renal insufficiency requiring hemodialysis;
7.Patients with severe electrolyte disorder and hematopathy;
8.Patients with various mental diseases;
9.Pregnant or lactating women, and women planning pregnancy or without contraception plan;
10.Patients with diabetic retinopathy (proliferative stage) and hemorrhagic diseases;
11.Patients known or suspected to be allergic to the drugs used in this study;
12.Participants in other clinical trials within 3 months.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting blood glucose;2h postprandial blood glucose;Glycosylated hemoglobin;Glycated Albumin;Echocardiography;
- Secondary Outcome Measures
Name Time Method Transforming growth factor-ß1;Procollagen III N-termi;Connective tissue growth factor;Urine acetone bodies;Uric acid;Carboxyterminal of type I procollagen;